New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:43 EDTINSMInsmed met 'much more meaningful' secondary endpoint, says Piper Jaffray
Piper Jaffray says Insmed's Phase 2 Study of Arikayce for nontuberculous mycobacteria met the "much more meaningful and clinically relevant" secondary endpoint of culture conversion while missing the less clinically relevant primary endpoint of sputum density. Piper says the drug works and thinks the stock could end up staying close to where it is currently given the split decision on endpoints. The firm reiterates an Overweight rating on Insmed.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:07 EDTINSMInsmed provides end of year regulatory and clinical update
Subscribe for More Information
December 11, 2014
09:17 EDTINSMInsmed management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use